- Catumaxomab
drugbox
type = mab
source =Rat -murine hybrid
target = EpCAMCD3
CAS_number = 509077-98-9
ATC_prefix = L01
ATC_suffix = XC09
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Catumaxomab (brand name Removab) is a
rat -murine hybridmonoclonal antibody which is used to treat some cancers such as platinum-refractory ovarian cancer, malignant ascites, and gastric cancer. It binds to antigenCD3 and is also trifunctional. It is in clinical trials in the United States currently and is used in Europe. It is produced by Fresenius Biotech and Trion Pharma (Germany).It works by linking T-lymphocytes with the cancer cells.
Wikimedia Foundation. 2010.